Literature DB >> 15042326

Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities?

Renato A Valdés Olmos, Cornelis A Hoefnagel.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15042326     DOI： 10.1007/s00259-004-1494-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  13 in total

1.  Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy Committee.

Authors:  C A Hoefnagel; S E Clarke; M Fischer; J F Chatal; V J Lewington; S Nilsson; L Troncone; M R Vieira
Journal:  Eur J Nucl Med       Date:  1999-03

2.  Radioisotope therapy and clinical trial design: the need for consensus and innovation.

Authors:  Alexander J B McEwan
Journal:  J Nucl Med       Date:  2002-01       Impact factor: 10.057

3.  Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.

Authors:  Rosa Sciuto; Anna Festa; Sandra Rea; Rosella Pasqualoni; Serenella Bergomi; Germana Petrilli; Carlo L Maini
Journal:  J Nucl Med       Date:  2002-01       Impact factor: 10.057

4.  Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Authors:  S M Tu; R E Millikan; B Mengistu; E S Delpassand; R J Amato; L C Pagliaro; D Daliani; C N Papandreou; T L Smith; J Kim; D A Podoloff; C J Logothetis
Journal:  Lancet       Date:  2001-02-03       Impact factor: 79.321

5.  Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.

Authors:  Gregory A Yanik; John E Levine; Katherine K Matthay; James C Sisson; Barry L Shulkin; Brahm Shapiro; David Hubers; Susan Spalding; Tom Braun; James L M Ferrara; Raymond J Hutchinson
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

6.  [131I]MIBG as a first line treatment in advanced neuroblastoma.

Authors:  C A Hoefnagel; J De Kraker; R A Valdés Olmos; P A Voûte
Journal:  Q J Nucl Med       Date:  1995-12

7.  A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.

Authors:  Lance C Pagliaro; Ebrahim S Delpassand; Dallas Williams; Randall E Millikan; Shi-Ming Tu; Christopher J Logothetis
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

8.  Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study.

Authors:  Sigbjørn Smeland; Bjørn Erikstein; Magne Aas; Eva Skovlund; Siri Lothe Hess; Sophie Dorothea Fosså
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-08-01       Impact factor: 7.038

Review 9.  Future directions in radioimmunotherapy for B-cell lymphoma.

Authors:  Sandra J Horning
Journal:  Semin Oncol       Date:  2003-12       Impact factor: 4.929

10.  Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.

Authors:  C Grana; M Chinol; C Robertson; C Mazzetta; M Bartolomei; C De Cicco; M Fiorenza; M Gatti; P Caliceti; G Paganelli
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640
View more
  3 in total

1.  From the magic bullet to an effective therapy: the peptide experience.

Authors:  Luigi Mansi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

2.  Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals.

Authors:  H Palmedo; J Bucerius
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-15       Impact factor: 9.236

3.  Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer.

Authors:  Sergio Ricci; Giuseppe Boni; Ilaria Pastina; Dario Genovesi; Claudia Cianci; Serena Chiacchio; Cinzia Orlandini; Mariano Grosso; Abedallatif Alsharif; Aldo Chioni; Samantha Di Donato; Francesco Francesca; Cesare Selli; Domenico Rubello; Giuliano Mariani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-23       Impact factor: 10.057
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.